Get the Stockscreener App
223.07
1.83%
-4.16
After Hours:
223.20
0.13
+0.06%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $223.07, with a volume of 4.87M.
It is down -1.83% in the last 24 hours and up +10.68% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$227.23
Open:
$226.75
24h Volume:
4.87M
Relative Volume:
0.75
Market Cap:
$394.12B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
110.03
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+4.76%
1M Performance:
+10.68%
6M Performance:
-0.02%
1Y Performance:
+17.51%
1-Day Range:
$221.16
$228.58
1-Week Range:
$208.99
$230.47
52-Week Range:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
223.07 | 401.47B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,149.15 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.16 | 560.33B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
119.52 | 298.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
181.55 | 288.38B | 60.48B | 10.40B | 8.05B | 3.3297 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Inc. stock (US00287Y1091): FDA decision and pipeline catalysts keep focus on growth - AD HOC NEWS
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month? - The Globe and Mail
Inflammatory Bowel Disease Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly, Gilead - Barchart.com
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 - Lelezard
Is AbbVie Stock The Right Defensive Pick In This Volatile Market? - Trefis
AbbVie brings new blood cancer trial results to European doctors - Stock Titan
AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades' - Benzinga
AbbVie Stock Price Target $350: Why TIKR Model Shows Around 54% Upside From Here - TIKR.com
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? - The Globe and Mail
AbbVie (ABBV) Valuation Check After New Cancer And Migraine Drug Approvals - Yahoo Finance
AbbVie Stock's Real Strength Is How Little It Cares About the Market - Trefis
AbbVie (ABBV) Announces European Commission’s Approval of AQUIPTA® - Insider Monkey
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Why AbbVie Keeps Drawing Attention In Dividend Stock Coverage? - Kalkine Media
Final Trades: Coca Cola, Abbvie Inc, Sabra Health Care and UnitedHealth - CNBC
AbbVie, Oracle, Apple And More On CNBC's 'Final Trades' - Benzinga
AbbVie Inc (ABBV) Stock Price, Trades & News - GuruFocus
Biopharma bites: Ozempic's impact on kidney disease, OliX's raise and UK support for AbbVie's Elahere - FirstWord Pharma
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc Stock (ABBV) Closed Up by 3.53% on Jun 4: Key Drivers Unveiled - TradingKey
Final Trades: Abbvie, Entegris, Oracle and Apple - CNBC
AbbVie Loses Latest Challenge Against Mississippi Pharmacy Law - Bloomberg Law News
List of 17 Acquisitions by AbbVie (Jun 2026) - Tracxn
ALDX: Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership - TradingView
Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology? - TradingView
New Commercial Deal Helps AbbVie Secure English Funding For Elahere - Citeline News & Insights
AbbVie (ABBV) Secures NHS Approval for Ovarian Cancer Treatment Elahere - GuruFocus
AbbVie’s ovarian cancer drug Elahere greenlighted for NHS availability - Seeking Alpha
AbbVie Loses Miss. Discount Drug Law Challenge For Good - Law360
ABBV Stock Quote Price and Forecast - CNN
British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy - Reuters
Amgen Inc Stock (AMGN) Closed Up by 3.04% on Jun 3: Key Drivers Unveiled - TradingKey
AbbVie Inc. stock (US00287Y1091): Goldman Sachs healthcare conference appearance and steady NYSE tra - AD HOC NEWS
AbbVie Delivers 400% Returns Beating The S&P 500 by 139% - Yahoo Finance
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine - The Globe and Mail
Investors heavily search AbbVie Inc. (ABBV): Here is what you need to know - MSN
AbbVie stock: Is ABBV outperforming the healthcare sector? - MSN
EC approves AbbVie’s Aquipta for migraine - The Pharma Letter
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Inc stock (US00287Y1091): participation at Goldman Sachs healthcare conference in focus - AD HOC NEWS
Elite Laboratories Inc, AbbVie Inc, Par Health USA LLC, Sunstar Americas Inc, eVenus Pharmaceutical Lab Inc, Navinta LLC, PTS Consulting LLC, Makro Technologies Inc, Eagle Pharmaceuticals Inc, CMC GMP LLC Withdraw Approval Of 16 Abbreviated Ne - marketscreener.com
AbbVie (ABBV) to Attend Goldman Sachs Global Healthcare Conferen - GuruFocus
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic - The Motley Fool
AbbVie Inc. stock (US00287Y1091): conference appearance and EU migraine approval keep focus on pharm - AD HOC NEWS
AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO® - Insider Monkey
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Investing News Network
Is AbbVie Inc. (ABBV) Expanding Its Oncology Pipeline With New BPDCN Treatment Approval? - Insider Monkey
Bernstein Maintains AbbVie(ABBV.US) With Hold Rating - Moomoo
AbbVie (ABBV) Secures EU Approval for Aquipta as Migraine Treatm - GuruFocus
Stream AbbVie’s Goldman Sachs healthcare talk live or on replay - Stock Titan
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):